DBV Technologies | DBVT - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
DBV Technologies USD 461K 323.71K 2025-03
Esperion Therapeutics USD 22.64M 585K 2025-12
Galectin Therapeutics USD 1.27M 220K 2024-06
Halozyme Therapeutics USD 5.51M 597K 2026-03
Incyte USD 569K 13K 2026-03
Insmed USD 20.08M 517K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
United Therapeutics USD 3.1M 100K 2025-12